Voyager Therapeutics, Inc.: ARMISTICE CAPITAL, LLC discloses a stake of more than 5% (Schedule 13G)
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
Armistice Capital LLC disclosed a stake exceeding 5% in Voyager Therapeutics Inc. via a Schedule 13G filing with the SEC (accession 0001172661-26-005304). The exact share count and percentage were not specified in the filing headline. The disclosure signals a new or expanded activist or institutional position in the gene therapy developer, which investors often monitor for potential influence on strategy. Voyager has not commented on the filing. Watch for further 13G/13D amendments that clarify Armistice's intent and any resulting changes to Voyager's pipeline or capital allocation plans.
Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.
Named in this story
Armistice Capital, LLC, Voyager Therapeutics, Inc.